Effects of the strong CYP3A4 and P-glycoprotein inhibitor itraconazole on the pharmacokinetics of oral and intranasal zavegepant

被引：0
|
作者：
Bhardwaj, R. [1 ]
Malatesta, J. K. [2 ]
Stringfellow, J. [3 ]
Madonia, J. [4 ]
Anderson, M. [4 ]
Stock, D. A. [4 ]
Morris, B. A. [4 ]
Coric, V [5 ]
Croop, R. [5 ]
Bertz, R. [4 ]
机构：
[1] Certara Strateg Consulting, Integrated Drug Dev, Princeton, NJ USA
[2] Certara USA, Princeton, NJ USA
[3] Navitas Data Sci, Pottstown, PA USA
[4] Biohaven Pharmaceut, New Haven, CT USA
[5] Biohaven Pharmaceut Holding Co Ltd, New Haven, CT USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-163
引用
收藏
页码：140 / 141
页数：2
相关论文
共 50 条
  • [31] Concentrations and effects of inhaled budesonide are increased by the CYP3A4 inhibitor itraconazole
    Kivistö, KT
    Raaska, K
    Niemi, M
    Neuvonen, M
    Neuvonen, PJ
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R111 - R111
  • [32] Absorption of quinidine is influenced by intestinal P-glycoprotein and CYP3A4 in humans
    Glaeser, H
    Drescher, S
    Mürdter, T
    Eichelbaum, M
    Fromm, MF
    DRUG METABOLISM REVIEWS, 2003, 35 : 66 - 66
  • [33] Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4
    Cummins, CL
    Jacobsen, W
    Benet, LZ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03): : 1036 - 1045
  • [34] The effect of the CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of ZD6474 in healthy subjects
    Smith, R
    Oliver, S
    Ghahramani, P
    Kennedy, S
    Gilmore, E
    Duvauchelle, T
    Hammett, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 222S - 222S
  • [35] Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
    Wang, Hengbang
    Yang, Yun
    Chen, Zi
    Fu, Lei
    Yu, Min
    Jiang, Lixin
    Wang, Cunlin
    Men, Lichuang
    Minto, Ilisse
    Yang, Dajun
    Zhai, Yifan
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (09):
  • [36] Potent in vitro Inhibition of CYP3A4 and P-Glycoprotein by Rhodiola rosea
    Hellum, Bent H.
    Tosse, Anita
    Hoybakk, Kathrine
    Thomsen, Mette
    Rohloff, Jens
    Nilsen, Odd Georg
    PLANTA MEDICA, 2010, 76 (04) : 331 - 338
  • [37] Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor
    Gardiner, Philip
    Jauhiainen, Alexandra
    Palmer, Robert
    Maenpaa, Jukka
    Stenvall, Kristina
    Larsson, Bengt
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [38] EFFECTS OF A CYP3A4 INHIBITOR (ITRACONAZOLE) AND INDUCER (RIFAMPIN), AND UGT INHIBITOR (PROBENECID) ON THE PHARMACOKINETICS OF THE MULTI-KINASE INHIBITOR PEXIDARTINIB.
    Vandell, A. G.
    Duchin, K. L.
    Patel, S.
    Gajee, R.
    Zamora, C. A.
    Biernat, L.
    Chen, S.
    Wang, Q.
    Zhang, H.
    Zhang, L.
    Zahir, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S90 - S91
  • [39] Impact of saturation of CYP3A4 and P-glycoprotein in vivo on the prediction of intestinal availability
    Gertz, Michael
    Harrison, Anthony
    Davis, John
    Houston, J. Brian
    Galetin, Aleksandra
    DRUG METABOLISM REVIEWS, 2009, 41 : 29 - 30
  • [40] Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in Rats: Possible role of CYP3A4 and P-glycoprotein inhibition by myricetin
    Sang-Joon Choi
    Sang-Chul Shin
    Jun-Shik Choi
    Archives of Pharmacal Research, 2011, 34 : 309 - 315
12345